GlassScriptPhysician profile
Robert Murgia
NPI 1063804441
$5,883.10
in general payments reported to CMS, 2019-2025
24 companies · $499 in 2025
The $499 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $134 · 2021: $384 · 2022: $1,340 · 2023: $1,178 · 2024: $1,548 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,116 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,115.56 |
| Education | $109.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,881.93 | 2019-2025 | |
| Janssen Biotech, INC. | $1,014.95 | 2021-2024 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $673.96 | 2021-2024 | Olumiant, Taltz, Ebglyss |
| Arcutis Biotherapeutics, INC. | $513.84 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $261.54 | 2019-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $237.91 | 2022-2024 | Sotyktu |
| Incyte Corporation | $142.88 | 2022 | |
| Ucb, INC. | $137.22 | 2019-2024 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $132.43 | 2021-2023 | Absorica Ld, Winlevi, Ilumya |
| Novartis Pharmaceuticals Corporation | $119.89 | 2019 | |
| Almirall LLC | $118.94 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $108.53 | 2019 | |
| Allergan, INC. | $97.33 | 2019 | |
| Sanofi-Aventis U.S. LLC | $75.50 | 2020 | |
| Dermavant Sciences, INC. | $75.08 | 2023-2024 | Vtama |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $67.57 | 2019 | |
| Genzyme Corporation | $57.19 | 2020-2022 | |
| Organon LLC | $33.52 | 2023-2025 | Vtama, Hadlima |
| Regeneron Healthcare Solutions, INC. | $31.45 | 2020-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.00 | 2019 | |
| Pfizer INC. | $23.54 | 2022 | |
| Amgen INC. | $18.52 | 2025 | Otezla |
| Johnson & Johnson Health Care Systems INC. | $15.25 | 2024 | Tremfya |
| Strata Skin Sciences, INC. | $14.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Murgia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.